Skip to content

Evaluation of Rapid Hepatitis B Vaccination in Adults Prior to Living Kidney Transplantation

Evaluation of the Immunogenicity of an Accelerated Hepatitis B Vaccination Schedule in Adults Prior to Living-Donor Kidney Transplantation - Accelerated HBV Vaccination Immunogenicity in Adults Before LDKT

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs041260011
Enrollment
20
Registered
2026-04-28
Start date
2026-05-12
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic kidney failure prior to living-donor kidney transplantation Prior to living-donor kidney transplantation, Vaccination, Hepatitis B

Interventions

Accelerated HBV vaccination schedule

Sponsors

Hanai Shogo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients from whom written informed consent was obtained of their own free will after receiving a sufficient explanation and demonstrating adequate understanding prior to participation in this study. 2. Adult patients aged 18 years or older at the time of consent. 3. Patients awaiting living-donor kidney transplantation. 4. Patients who are negative for hepatitis B surface antibody (anti-HBs). 5. Patients with no prior history of hepatitis B vaccination.

Exclusion criteria

Exclusion criteria: 1. Patients scheduled to receive rituximab within 34 days. 2. Patients scheduled to undergo organ transplantation within 34 days. 3. Patients who are positive for hepatitis B surface antigen (HBsAg). 4. Patients for whom at least six months are anticipated before the scheduled date of transplantation. 5. Patients who have received rituximab within the past six months. 6. Patients who have experienced severe adverse events related to hepatitis B vaccination. 7. Patients currently participating in another interventional study that may interfere with the evaluation of this study. 8. Patients deemed inappropriate for inclusion in the study by the principal investigator or sub-investigators.

Design outcomes

Primary

MeasureTime frame
Seroconversion rate of anti-HBs prior to transplantation (or prior to rituximab administration in patients receiving rituximab)

Secondary

MeasureTime frame
Anti-HBs seroconversion rate four weeks after the third vaccine dose Anti-HBs seroconversion rate four weeks after the fourth vaccine dose Distribution of anti-HBs antibody titers at the above time points Number of cases with serious adverse events, systemic adverse reactions, and local adverse reactions

Contacts

Public ContactShogo Hanai

Fujita Health University Hospital

shogo.hanai1990@gmail.com+81-562-93-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026